Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pravastatin in Early Stage ADPKD
NCT03273413Phase 4Active, not recruiting
- Sponsor
- University of Colorado Denver
- Start
- Aug 2017
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in autosomal dominant polycystic kidney disease (ADPKD) comparing Placebo with Pravastatin (2 arms). Primary endpoint: Change in Total Kidney Volume at 2 years. Started Aug 2017; status: active, not recruiting.
02
Drugs
pravastatin
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on NCT03273413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03273413.